You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePargyline
Accession NumberDB01626
TypeSmall Molecule
GroupsApproved
DescriptionA monoamine oxidase inhibitor with antihypertensive properties. [PubChem]
Structure
Thumb
Synonyms
Eutonyl
Eutron
Pargyline
External Identifiers
  • Lopac-P-8013
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EutonylNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pargyline hydrochloride
Thumb
  • InChI Key: BCXCABRDBBWWGY-UHFFFAOYSA-N
  • Monoisotopic Mass: 195.08147716
  • Average Mass: 195.689
DBSALT000304
Categories
UNII9MV14S8G3E
CAS number555-57-7
WeightAverage: 159.2276
Monoisotopic: 159.104799421
Chemical FormulaC11H13N
InChI KeyDPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
IUPAC Name
benzyl(methyl)(prop-2-yn-1-yl)amine
SMILES
CN(CC#C)CC1=CC=CC=C1
Pharmacology
IndicationFor the treatment of moderate to severe hypertension.
Structured Indications Not Available
PharmacodynamicsPargyline is a monoamine oxidase B (MAO-B) inhibitor with antihypertensive properties. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis.
Mechanism of actionMAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.
TargetKindPharmacological actionActionsOrganismUniProt ID
Amine oxidase [flavin-containing] BProteinyes
inhibitor
HumanP27338 details
Amine oxidase [flavin-containing] AProteinunknown
inhibitor
HumanP21397 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePargyline may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePargyline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePargyline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePargyline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEPargyline may increase the hypertensive activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcarbosePargyline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololPargyline may increase the hypotensive activities of Acebutolol.Approved
AlbiglutidePargyline may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Pargyline.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Pargyline.Approved, Investigational
AliskirenPargyline may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pargyline.Approved, Investigational
AlogliptinPargyline may increase the hypoglycemic activities of Alogliptin.Approved
AlprenololPargyline may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Pargyline.Approved
AmbrisentanPargyline may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostinePargyline may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptinePargyline may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylinePargyline may increase the serotonergic activities of Amitriptyline.Approved
AmlodipinePargyline may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Pargyline is combined with Amoxapine.Approved
AmphetaminePargyline may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Pargyline.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pargyline is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Arformoterol.Approved, Investigational
AtenololPargyline may increase the hypotensive activities of Atenolol.Approved
AtomoxetinePargyline may increase the central neurotoxic activities of Atomoxetine.Approved
AtropinePargyline may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Bambuterol.Approved
BenazeprilPargyline may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePargyline may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinPargyline may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetaminePargyline may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilPargyline may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Pargyline.Approved
BetaxololPargyline may increase the hypotensive activities of Betaxolol.Approved
BethanidinePargyline may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Pargyline is combined with Bezafibrate.Approved
BimatoprostPargyline may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololPargyline may increase the hypotensive activities of Bisoprolol.Approved
BosentanPargyline may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumPargyline may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pargyline is combined with Brimonidine.Approved
BrimonidinePargyline may increase the hypotensive activities of Brimonidine.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Pargyline.Approved, Investigational
BupranololPargyline may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pargyline.Approved, Illicit, Investigational, Vet Approved
BupropionPargyline may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pargyline.Approved, Investigational
CabergolineThe metabolism of Cabergoline can be decreased when combined with Pargyline.Approved
CanagliflozinPargyline may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanPargyline may increase the hypotensive activities of Candesartan.Approved
CandoxatrilPargyline may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPargyline may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pargyline.Approved, Investigational
CaroxazonePargyline may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololPargyline may increase the hypotensive activities of Carteolol.Approved
CarvedilolPargyline may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPargyline may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazidePargyline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenterminePargyline may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamidePargyline may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidonePargyline may increase the hypotensive activities of Chlorthalidone.Approved
CilazaprilPargyline may increase the hypotensive activities of Cilazapril.Approved
CirazolinePargyline may increase the hypertensive activities of Cirazoline.Experimental
CitalopramPargyline may increase the serotonergic activities of Citalopram.Approved
ClemastinePargyline may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Clenbuterol.Approved, Vet Approved
ClomipraminePargyline may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidinePargyline may increase the hypotensive activities of Clonidine.Approved
CryptenaminePargyline may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Pargyline.Approved
CyclothiazidePargyline may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadinePargyline may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinPargyline may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetinePargyline may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinPargyline may increase the hypotensive activities of Debrisoquin.Approved
DeserpidinePargyline may increase the hypotensive activities of Deserpidine.Approved
DesipraminePargyline may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxinePargyline may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidatePargyline may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetaminePargyline may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanPargyline may increase the serotonergic activities of Dextromethorphan.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Pargyline.Approved
DiethylpropionPargyline may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazinePargyline may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Pargyline.Approved
DiltiazemPargyline may increase the hypotensive activities of Diltiazem.Approved
DipivefrinThe risk or severity of adverse effects can be increased when Pargyline is combined with Dipivefrin.Approved
DisopyramidePargyline may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamidePargyline may increase the hypotensive activities of Dorzolamide.Approved
DosulepinPargyline may increase the serotonergic activities of Dosulepin.Approved
DoxapramPargyline may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinPargyline may increase the hypotensive activities of Doxazosin.Approved
DoxepinPargyline may increase the serotonergic activities of Doxepin.Approved
DoxylaminePargyline may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Pargyline is combined with Droxidopa.Approved, Investigational
DulaglutidePargyline may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetinePargyline may increase the serotonergic activities of Duloxetine.Approved
EfonidipinePargyline may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Pargyline.Approved, Investigational
EmpagliflozinPargyline may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilPargyline may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPargyline may increase the hypotensive activities of Enalaprilat.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pargyline.Approved, Investigational
EphedraThe risk or severity of adverse effects can be increased when Pargyline is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrinePargyline may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolPargyline may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPargyline may increase the hypotensive activities of Eprosartan.Approved
ErgotaminePargyline may increase the hypertensive activities of Ergotamine.Approved
EscitalopramPargyline may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapinePargyline may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pargyline.Approved
EtoperidonePargyline may increase the serotonergic activities of Etoperidone.Approved
ExenatidePargyline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipinePargyline may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Pargyline is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamPargyline may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Pargyline.Approved, Illicit, Investigational, Vet Approved
FluoxetinePargyline may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxaminePargyline may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Formoterol.Approved, Investigational
FosinoprilPargyline may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Pargyline.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Pargyline.Approved, Vet Approved
GliclazidePargyline may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePargyline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePargyline may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePargyline may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzPargyline may increase the hypotensive activities of Guanabenz.Approved
GuanadrelPargyline may increase the hypotensive activities of Guanadrel.Approved
GuanethidinePargyline may increase the hypotensive activities of Guanethidine.Approved
GuanfacinePargyline may increase the hypotensive activities of Guanfacine.Approved, Investigational
HexamethoniumPargyline may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazinePargyline may increase the hypertensive activities of Hydracarbazine.Approved
HydralazinePargyline may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePargyline may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydrocodone.Approved, Illicit
HydroflumethiazidePargyline may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromidePargyline may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.Approved
IloprostIloprost may increase the hypotensive activities of Pargyline.Approved, Investigational
ImidaprilPargyline may increase the hypotensive activities of Imidapril.Investigational
ImipraminePargyline may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.Approved
IndalpinePargyline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamidePargyline may increase the hypotensive activities of Indapamide.Approved
IndenololPargyline may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminPargyline may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartPargyline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPargyline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePargyline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePargyline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPargyline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPargyline may increase the hypoglycemic activities of Insulin Lispro.Approved
IproclozidePargyline may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidPargyline may increase the hypertensive activities of Iproniazid.Withdrawn
IrbesartanPargyline may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Pargyline.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Pargyline is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline.Approved
IsradipinePargyline may increase the hypotensive activities of Isradipine.Approved
KetanserinPargyline may increase the hypotensive activities of Ketanserin.Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pargyline.Approved, Nutraceutical
LabetalolPargyline may increase the hypotensive activities of Labetalol.Approved
LacidipinePargyline may increase the hypotensive activities of Lacidipine.Approved
LanreotidePargyline may increase the hypoglycemic activities of Lanreotide.Approved
LatanoprostPargyline may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipinePargyline may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pargyline.Approved
LevomilnacipranPargyline may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinPargyline may increase the hypertensive activities of Levonordefrin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Pargyline is combined with Linezolid.Approved, Investigational
LiraglutidePargyline may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetaminePargyline may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilPargyline may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Pargyline.Approved
LithiumThe risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.Approved
LofexidinePargyline may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanPargyline may increase the hypotensive activities of Losartan.Approved
Lu AA21004The metabolism of Lu AA21004 can be decreased when combined with Pargyline.Investigational
MacitentanPargyline may increase the hypotensive activities of Macitentan.Approved
ManidipinePargyline may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pargyline.Approved
MebanazinePargyline may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylaminePargyline may increase the hypotensive activities of Mecamylamine.Approved
MecaserminPargyline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedronePargyline may increase the hypertensive activities of Mephedrone.Investigational
MephenterminePargyline may increase the hypertensive activities of Mephentermine.Approved
MequitazinePargyline may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolPargyline may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminPargyline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Methadone.Approved
MethamphetaminePargyline may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoxaminePargyline may increase the hypertensive activities of Methoxamine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Pargyline is combined with Methyldopa.Approved
Methylene bluePargyline may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidatePargyline may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololPargyline may increase the hypotensive activities of Metipranolol.Approved
MetolazonePargyline may increase the hypotensive activities of Metolazone.Approved
MetoprololPargyline may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePargyline may increase the hypotensive activities of Metyrosine.Approved
MianserinPargyline may increase the neurotoxic activities of Mianserin.Approved
MibefradilPargyline may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrinePargyline may increase the hypertensive activities of Midodrine.Approved
MifepristonePargyline may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPargyline may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranPargyline may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Pargyline.Approved
MinoxidilPargyline may increase the hypotensive activities of Minoxidil.Approved
MirtazapinePargyline may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAPargyline may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Pargyline is combined with Moclobemide.Approved
MoexiprilPargyline may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Pargyline.Approved
MorphineThe risk or severity of adverse effects can be increased when Pargyline is combined with Morphine.Approved, Investigational
MoxonidinePargyline may increase the hypotensive activities of Moxonidine.Approved
NadololPargyline may increase the hypotensive activities of Nadolol.Approved
NaftopidilPargyline may increase the hypotensive activities of Naftopidil.Investigational
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Pargyline.Approved, Investigational
NateglinidePargyline may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololPargyline may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodonePargyline may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamidePargyline may increase the hypertensive activities of Nialamide.Withdrawn
NicardipinePargyline may increase the hypotensive activities of Nicardipine.Approved
NicorandilPargyline may increase the hypotensive activities of Nicorandil.Approved
NiguldipinePargyline may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePargyline may increase the hypotensive activities of Nilvadipine.Approved
NimodipinePargyline may increase the hypotensive activities of Nimodipine.Approved
NisoldipinePargyline may increase the hypotensive activities of Nisoldipine.Approved
NitrendipinePargyline may increase the hypotensive activities of Nitrendipine.Approved
NitroprussidePargyline may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrinePargyline may increase the hypertensive activities of Norepinephrine.Approved
NortriptylinePargyline may increase the serotonergic activities of Nortriptyline.Approved
ObinutuzumabPargyline may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinPargyline may increase the hypertensive activities of Octamoxin.Withdrawn
OctreotidePargyline may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Pargyline is combined with Olanzapine.Approved, Investigational
OlmesartanPargyline may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Olodaterol.Approved
OmapatrilatPargyline may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolPargyline may increase the serotonergic activities of Opipramol.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Orciprenaline.Approved
OxprenololPargyline may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pargyline.Approved, Investigational, Vet Approved
ParoxetinePargyline may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotidePargyline may increase the hypoglycemic activities of Pasireotide.Approved
PenbutololPargyline may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidinePargyline may increase the hypoglycemic activities of Pentamidine.Approved
PentoliniumPargyline may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Pargyline.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Pargyline.Approved, Vet Approved, Withdrawn
PerindoprilPargyline may increase the hypotensive activities of Perindopril.Approved
PethidinePargyline may increase the serotonergic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of Pargyline.Approved
PheniprazinePargyline may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoxybenzaminePargyline may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePargyline may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhenterminePargyline may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolaminePargyline may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePargyline may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Pargyline.Approved, Illicit
PinacidilPargyline may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPargyline may increase the hypotensive activities of Pindolol.Approved
PioglitazonePargyline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Pirbuterol.Approved
PirlindolePargyline may increase the hypertensive activities of Pirlindole.Approved
PivhydrazinePargyline may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenPargyline may increase the anticholinergic activities of Pizotifen.Approved
PolythiazidePargyline may increase the hypotensive activities of Polythiazide.Approved
PramlintidePargyline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinPargyline may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Procaterol.Approved
PropranololPargyline may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylinePargyline may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Pargyline.Investigational
PseudoephedrinePargyline may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilPargyline may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Pargyline.Approved
RamiprilPargyline may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Pargyline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Pargyline.Approved
RemikirenPargyline may increase the hypotensive activities of Remikiren.Approved
RepaglinidePargyline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnaminePargyline may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Pargyline is combined with Reserpine.Approved
RilmenidinePargyline may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatPargyline may increase the hypotensive activities of Riociguat.Approved
RitobegronPargyline may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Pargyline is combined with Ritodrine.Approved
RituximabPargyline may increase the hypotensive activities of Rituximab.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Pargyline.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Pargyline.Approved, Investigational
RosiglitazonePargyline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazinePargyline may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Salmeterol.Approved
SaprisartanPargyline may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinPargyline may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Pargyline.Approved, Investigational, Vet Approved
SelexipagPargyline may increase the hypotensive activities of Selexipag.Approved
SertralinePargyline may increase the serotonergic activities of Sertraline.Approved
SildenafilSildenafil may increase the antihypertensive activities of Pargyline.Approved, Investigational
SitagliptinPargyline may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanPargyline may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilPargyline may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Pargyline.Approved, Investigational
SulfadiazinePargyline may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePargyline may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazolePargyline may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Pargyline.Approved, Investigational
SunitinibPargyline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Pargyline.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pargyline.Approved
TelmisartanPargyline may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPargyline may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.Approved
TerlipressinPargyline may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Pargyline.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pargyline.Approved
TetryzolinePargyline may increase the hypertensive activities of Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Pargyline.Approved
TibolonePargyline may increase the hypotensive activities of Tibolone.Approved
TicrynafenPargyline may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololPargyline may increase the hypotensive activities of Timolol.Approved
TolazamidePargyline may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePargyline may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePargyline may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pargyline.Approved, Withdrawn
ToloxatonePargyline may increase the hypertensive activities of Toloxatone.Approved
TorasemidePargyline may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Pargyline.Approved, Investigational
TrandolaprilPargyline may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylaminePargyline may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Pargyline.Approved
TravoprostPargyline may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Trazodone.Approved, Investigational
TreprostinilPargyline may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazidePargyline may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinPargyline may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPargyline may increase the hypotensive activities of Trimethaphan.Approved
TrimipraminePargyline may increase the serotonergic activities of Trimipramine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Pargyline.Approved, Investigational
UnoprostonePargyline may increase the hypotensive activities of Unoprostone.Approved
ValsartanPargyline may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Pargyline.Approved
VenlafaxinePargyline may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Pargyline.Approved
VinpocetinePargyline may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pargyline.Approved
XylometazolinePargyline may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Pargyline.Approved, Vet Approved
ZimelidinePargyline may increase the serotonergic activities of Zimelidine.Withdrawn
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Pargyline.Approved, Investigational
Food Interactions
  • Food increases the oral bioavailability by 3-5 fold.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC02LL01C02KC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9504
Blood Brain Barrier+0.9568
Caco-2 permeable+0.8188
P-glycoprotein substrateNon-substrate0.6641
P-glycoprotein inhibitor INon-inhibitor0.9864
P-glycoprotein inhibitor IINon-inhibitor0.9357
Renal organic cation transporterNon-inhibitor0.5518
CYP450 2C9 substrateNon-substrate0.8061
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6977
CYP450 1A2 substrateNon-inhibitor0.7981
CYP450 2C9 inhibitorNon-inhibitor0.9213
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.945
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7826
Ames testNon AMES toxic0.9413
CarcinogenicityNon-carcinogens0.5475
BiodegradationNot ready biodegradable0.9459
Rat acute toxicity2.6935 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7258
hERG inhibition (predictor II)Non-inhibitor0.8819
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0998 mg/mLALOGPS
logP2.05ALOGPS
logP2.14ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)8.13ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity52.18 m3·mol-1ChemAxon
Polarizability18.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48. [PubMed:1794016 ]
  2. Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 Jul;19(1):11-22. [PubMed:9673855 ]
  3. Authors unspecified: Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int. 2002 Aug;11(60):108-11. [PubMed:12199263 ]
  4. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956 ]
  5. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926 ]
  6. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016 ]
  7. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  8. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  9. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  10. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  11. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
  12. Villeneuve C, Caudrillier A, Ordener C, Pizzinat N, Parini A, Mialet-Perez J: Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. doi: 10.1152/ajpheart.00345.2009. Epub 2009 Jun 19. [PubMed:19542488 ]
  13. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606 ]
  14. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  2. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  3. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
  5. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606 ]
  6. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 15:04 / Updated on August 17, 2016 12:23